Novel serotonin 5-HT
5-HT2A receptors
Aggregation
Antiplatelet
Hydantoin
Imidazolidinine-2,4-dione
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
31
12
2020
accepted:
19
05
2021
revised:
13
05
2021
pubmed:
12
6
2021
medline:
28
1
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
Antiplatelet drugs have been used in the treatment of acute coronary syndromes and for the prevention of recurrent events. Unfortunately, many patients remain resistant to the available antiplatelet treatment. Therefore, there is a clinical need to synthesize novel antiplatelet agents, which would be associated with different pathways of platelet aggregation, to develop an alternative or additional treatment for resistant patients. Recent studies have revealed that 5-HT Based on the structures of the conventional 5-HT Functional bioassays revealed some of the synthesized compounds to be moderate antagonists of 5-HT Our study confirmed that the 5-HT
Sections du résumé
BACKGROUND
BACKGROUND
Antiplatelet drugs have been used in the treatment of acute coronary syndromes and for the prevention of recurrent events. Unfortunately, many patients remain resistant to the available antiplatelet treatment. Therefore, there is a clinical need to synthesize novel antiplatelet agents, which would be associated with different pathways of platelet aggregation, to develop an alternative or additional treatment for resistant patients. Recent studies have revealed that 5-HT
METHODS
METHODS
Based on the structures of the conventional 5-HT
RESULTS
RESULTS
Functional bioassays revealed some of the synthesized compounds to be moderate antagonists of 5-HT
CONCLUSIONS
CONCLUSIONS
Our study confirmed that the 5-HT
Identifiants
pubmed: 34115343
doi: 10.1007/s43440-021-00284-6
pii: 10.1007/s43440-021-00284-6
pmc: PMC8460535
doi:
Substances chimiques
Hydantoins
0
Platelet Aggregation Inhibitors
0
Serotonin 5-HT2 Receptor Antagonists
0
Mianserin
250PJI13LM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1361-1372Subventions
Organisme : Uniwersytet Jagielloński Collegium Medicum
ID : K/ZDS/006208
Organisme : Uniwersytet Jagielloński Collegium Medicum
ID : K/ZDS/006235
Organisme : Uniwersytet Jagielloński Collegium Medicum
ID : N42/DBS/000020
Organisme : Uniwersytet Jagielloński Collegium Medicum
ID : N42/DBS/000139
Informations de copyright
© 2021. The Author(s).
Références
Mo F, Li J, Yan Y, Wu W, Lai S. Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis. Drug Des Devel Ther. 2018;12:3583–94. https://doi.org/10.2147/DDDT.S166544 .
doi: 10.2147/DDDT.S166544
pubmed: 30498334
pmcid: 6207225
Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet. 2015;386:292–302. https://doi.org/10.1016/S0140-6736(15)60213-6 .
doi: 10.1016/S0140-6736(15)60213-6
pubmed: 25777663
Luna M, Holper EM. Use of novel antiplatelet agents in acute coronary syndromes. Curr Atheroscler Rep. 2015;17:12. https://doi.org/10.1007/s11883-014-0483-4 .
doi: 10.1007/s11883-014-0483-4
Capranzano P, Capodanno D. Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert Rev Cardiovasc Ther. 2013;11:307–17. https://doi.org/10.1586/erc.13.3 .
doi: 10.1586/erc.13.3
pubmed: 23469911
Duerschmied D, Ahrens I, Mauler M, Brandt C, Weidner S, Bode C, Moser M. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. PLoS ONE. 2012;7:e32656. https://doi.org/10.1371/journal.pone.0032656 .
doi: 10.1371/journal.pone.0032656
pubmed: 22384279
pmcid: 3287984
Floyd CN, Ferro A. Antiplatelet drug resistance: molecular insights and clinical implications. Prostaglandins Other Lipid Mediat. 2015;120:21–7. https://doi.org/10.1016/j.prostaglandins.2015.03.011 .
doi: 10.1016/j.prostaglandins.2015.03.011
pubmed: 25868910
Kubacka M, Kazek G, Kotańska M, Filipek B, Waszkielewicz AM, Mogilski S. Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT 2A and α 2-adrenoceptor antagonistic properties A comparison with ketanserin sarpogrelate prazosin yohimbine and ARC239. Eur J Pharmacol. 2018;818:263–70. https://doi.org/10.1016/j.ejphar.2017.10.053 .
doi: 10.1016/j.ejphar.2017.10.053
pubmed: 29111111
Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2006;22:27–54. https://doi.org/10.1111/j.1527-3466.2004.tb00130.x .
doi: 10.1111/j.1527-3466.2004.tb00130.x
Mauler M, Herr N, Schoenichen C, Witsch T, Marchini T, Härdtner C, et al. Platelet serotonin aggravates myocardial ischemia/reperfusion injury via neutrophil degranulation. Circulation. 2019;139:918–31. https://doi.org/10.1161/CIRCULATIONAHA.118.033942 .
doi: 10.1161/CIRCULATIONAHA.118.033942
pubmed: 30586717
pmcid: 6370531
Lee DH, Chun EJ, Hur JH, Min SH, Lee JE, Oh TJ, et al. Effect of sarpogrelate a selective 5-HT2A receptor antagonist on characteristics of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. 2017;257:47–54. https://doi.org/10.1016/j.atherosclerosis.2016.12.011 .
doi: 10.1016/j.atherosclerosis.2016.12.011
pubmed: 28068560
Czopek A, Zagorska A, Kolaczkowski M, Bucki A, Gryzlo B, Rychtyk J, et al. New spirohydanoin derivatives—synthesis pharmacological evaluation and molecular modeling study. Acta Pol Pharm. 2016;73:1545–54.
pubmed: 29634109
Czopek A, Byrtus H, Kołaczkowski M, Pawłowski M, Dybała M, Nowak G, et al. Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2 4-dione derivatives Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem. 2010;45:1295–303. https://doi.org/10.1016/j.ejmech.2009.11.053 .
doi: 10.1016/j.ejmech.2009.11.053
pubmed: 20060623
Czopek A, Kołaczkowski M, Bucki A, Byrtus H, Pawłowski M, Kazek G, Bojarski AJ, et al. Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent. Bioorganic Med Chem. 2015;23:3436–47. https://doi.org/10.1016/j.bmc.2015.04.026 .
doi: 10.1016/j.bmc.2015.04.026
Shah UH, Gaitonde SA, Moreno JL, Glennon RA, Dukat M, González-Maeso J. Revised pharmacophore model for 5-HT2A receptor antagonists derived from the atypical antipsychotic agent risperidone. ACS Chem Neurosci. 2019;10:2318–31. https://doi.org/10.1021/acschemneuro.8b00637 .
doi: 10.1021/acschemneuro.8b00637
pubmed: 30609893
Bagley JR, Thomas SA, Rudo FG, Spencer HK, Doorley BM, Ossipov MH, et al. New l-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics. J Med Chem. 1991;34:827–41. https://doi.org/10.1021/jm00106a051 .
doi: 10.1021/jm00106a051
pubmed: 1847432
Kurys BE, Fink DM, Freed BS, Merriman GH (1998) N-(pyridinylamino)isoindolines and related compounds. World patent, WO 98/29407, 9 July.
Truchon JF, Bayly CI. Evaluating virtual screening methods: good and bad metrics for the “early recognition” problem. J Chem Inf Model. 2007;47:488–508. https://doi.org/10.1021/ci600426e .
doi: 10.1021/ci600426e
pubmed: 17288412
Bucki A, Marcinkowska M, Śniecikowska J, Zagórska A, Jamrozik M, Pawłowski M, et al. Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1 2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). Eur J Med Chem. 2020. https://doi.org/10.1016/j.ejmech.2020.112149 .
doi: 10.1016/j.ejmech.2020.112149
pubmed: 33022582
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, et al. Structural features for functional selectivity at serotonin receptors. Science (80-). 2013;340:615–9. https://doi.org/10.1126/science.1232808 .
doi: 10.1126/science.1232808
Stegner D, Nieswandt B. Platelet receptor signaling in thrombus formation. J Mol Med. 2011;89:109–21. https://doi.org/10.1007/s00109-010-0691-5 .
doi: 10.1007/s00109-010-0691-5
pubmed: 21058007
Belcher P, Drake-Holland A, Noble M. The antiplatelet drug target in atherosclerotic diseases. Cardiovasc Hematol Disord Targets. 2012;6:43–55. https://doi.org/10.2174/187152906776092631 .
doi: 10.2174/187152906776092631
Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT 2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004;104:59–81. https://doi.org/10.1016/j.pharmthera.2004.08.005 .
doi: 10.1016/j.pharmthera.2004.08.005
pubmed: 15500909
Adams JW, Ramirez J, Shi Y, Thomsen W, Frazer J, Morgan M, et al. APD791 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy) phenyl)benzamide a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile pharmacokinetics platelet activity and vascular biology. J Pharmacol Exp Ther. 2009;331:96–103. https://doi.org/10.1124/jpet.109.153189 .
doi: 10.1124/jpet.109.153189
pubmed: 19628629